Navidea Biopharmaceuticals, Inc. announced the resignation of Jed A. Latkin as Chief Executive Officer of the Company effective October 24, 2021. An Office of the CEO including three members of the Company?s Board of Directors has been established to lead the Company on an interim basis while the next Chief Executive Officer of the Company is identified with the assistance of an executive search firm. The Office of the CEO consists of three Board members, including the Chairman, Vice Chairman and Thomas Farb, and the Company?s Senior Vice President and Chief Medical Officer, Michael Rosol, Ph.D., and the Company?s Vice President of Finance and Administration, Erika Eves.